Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.

Discover how local therapy options like radiotherapy and radical prostatectomy can significantly improve overall survival rates in cN1 prostate cancer patients.

Discover how your specialty stacks up in terms of hourly compensation and work-life balance; this analysis offers a fresh perspective on physician earnings.

The increasing acquisition of oncology practices by private equity firms poses new challenges to healthcare ethics and operations. Stay informed and be prepared to advocate for patient-centric reforms.

Discover the emerging evidence on the cancer risks associated with commonly prescribed medications and what it means for your prescribing habits.

Discover how the FDA-approved Invitae’s Common Hereditary Cancers Panel can enhance your approach to early cancer detection and personalized treatment planning.